NASDAQ:ELVN Enliven Therapeutics Q2 2025 Earnings Results & Report $39.28 -0.21 (-0.53%) Closing price 04:00 PM EasternExtended Trading$39.28 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Enliven Therapeutics beat analyst earnings expectations in its Q2 2025 results, released August 13, 2025. The company reported EPS of -$0.49 versus the -$0.53 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 13, 2025TimeBefore Market OpensConference Call4:00 PM ET Enliven Therapeutics EPS ResultsActual EPS-$0.49Consensus EPS -$0.53Beat/MissBeat by +$0.04One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersEnliven Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsEnliven Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 9, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Enliven Therapeutics Q2 2025 Earnings FAQ Did Enliven Therapeutics beat earnings estimates for Q2 2025? Enliven Therapeutics (NASDAQ:ELVN) reported earnings of -$0.49 per share for Q2 2025, beating the consensus estimate of -$0.53. The report was announced on Wednesday, August 13, 2025. When is Enliven Therapeutics' next earnings date? Enliven Therapeutics' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Enliven Therapeutics on the company's earnings history page. Enliven Therapeutics Earnings HeadlinesEnliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this YearOctober 14 at 4:30 PM | prnewswire.comWhy Enliven Therapeutics' (ELVN) ENABLE-2 Trial Design Raises New Questions About Its CML StrategyOctober 10, 2026 | finance.yahoo.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.October 14 at 1:00 AM | Awesomely (Ad)Enliven Therapeutics Announces FDA Alignment On ENABLE-2 Pivotal Phase 3 Trial Design For Relcobatinib In Previously Treated Chronic Myeloid LeukemiaOctober 7, 2026 | marketscreener.comMEnliven Gets FDA Alignment For Phase 3 Relcobatinib Trial In Blood CancerOctober 7, 2026 | rttnews.comFDA agrees ENABLE-2 Phase III trial design for Enliven’s relcobatinibOctober 7, 2026 | yahoo.comSee More Enliven Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Enliven Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enliven Therapeutics and other key companies, straight to your email. Email Address About Enliven TherapeuticsEnliven Therapeutics (NASDAQ:ELVN) (NASDAQ: ELVN) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company seeks to develop therapies designed to address significant unmet needs in oncology, with an emphasis on targeted treatments that may offer improved efficacy, safety, or durability. Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven cancers. Both programs are orally administered targeted therapies and are being evaluated through clinical development. The company was founded in 2019 and is headquartered in Boulder, Colorado. As a development-stage biotechnology company, Enliven’s operations are primarily focused on research, clinical studies, regulatory activities, and advancing its oncology pipeline toward potential commercialization.View Enliven Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
